Abstract
The Food and Drug Administration (FDA) approval of sipuleucel-T1 as the first therapeutic cancer vaccine represents a major stride for this field. Sipuleucel-T consists of autologous peripheral blood mononuclear cells, including antigen-presenting cells that have been activated ex vivo with a recombinant fusion protein. In addition to this vaccine, numerous other vaccine platforms are currently demonstrating evidence of patient benefit in multicenter, randomized Phase II and Phase III studies in a range of human cancers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
